Released by Kim Brown with the Longview Regional Medical Center:
LONGVIEW, TX - Longview Regional Medical Center and Dr. Rajeev Singh are making history, again! Due to a the latest technology from Cordis Corporation, a Johnson & Johnson company, a new 2.25 mm CYPHER® Sirolimus-eluting Coronary Stent is making a big difference in the treatment of coronary blockages in small vessels in a local patient, which is often a difficult situation to treat.
On September 22, 2009, Dr. Rajeev Singh, MD with the Diagnostic Clinic of Longview Cardiology Group was the first physician in the State of Texas and the third physician in the Nation to successfully implant the new 2.25 mm CYPHER® Stent on a local high-risk patient. On September 21, 2009, Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide.
"Many types of patients have small vessel disease, including women and those with certain other medical conditions. Small vessels in a patient can be challenging", declared Dr. Singh. "It is very beneficial for interventionalists and their patients to now have access to the CYPHER® Stent, especially those patients who are specific for these complex cases, such as high risk patients (diabetics especially). Small coronary vessels have been associated with an increased risk of re-blockage (restenosis) after stent implantation, which requires another procedure to re-open the vessel. The benefits of the CYPHER® Stent help to limit the regrowth of cells", he added.
At two years of follow up, the clinical trial results proved that patients receiving the CYPHER® Stent had significantly better clinical outcomes than those patients receiving a bare metal stent. In fact, use of the CYPHER® Stent led to an 82 percent reduction in restenosis compared to a bare metal stent (p<0.05) at six months.
Jim Kendrick, Chief Executive Officer at Longview Regional Medical Center affirmed, "Quality improvement and technology are both complex and demanding progressions. We (Longview Regional Medical Center) are thankful for the development these companies provide and their commitment to improve the health of the public. We are even more grateful to the excellent and highly skilled physicians on our medical staff that make these services available to our patients and our community. Together, we continue to be the leader in Quality Excellence, life saving technology and treatments, and continue to provide a superlative hospital experience for our patients".
About the CYPHER® Stent
The CYPHER® Stent has been chosen by cardiologists worldwide to treat nearly four million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 200 randomized and nonrandomized studies that examine the performance of the CYPHER® Stent in a broad range of patients. A number of these studies have data now out to seven years.
For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.
About Cordis Corporation
For more than 50 years, Cordis Corporation, a Johnson & Johnson company, has been a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease.